Publication:
Edaravone ameliorates the adverse effects of valproic acid toxicity in small intestine

Simple item page
dc.contributor.authorYARAT, AYŞEN
dc.contributor.authorsOktay, S.; Alev, B.; Tunali, S.; Emekli-Alturfan, E.; Tunali-Akbay, T.; Koc-Ozturk, L.; Yanardag, R.; Yarat, A.
dc.date.accessioned2022-03-13T12:50:02Z
dc.date.available2022-03-13T12:50:02Z
dc.date.issued2015
dc.description.abstractValproic acid (VPA) is a drug used for the treatment of epilepsy, bipolar psychiatric disorders, and migraine. Previous studies have reported an increased generation of reactive oxygen species and oxidative stress in the toxic mechanism of VPA. Edaravone, a free radical scavenger for clinical use, can quench free radical reaction by trapping a variety of free radical species. In this study, effect of edaravone on some small intestine biochemical parameters in VPA-induced toxicity was investigated. Thirty seven Sprague Dawley female rats were randomly divided into four groups. The groups include control group, edaravone (30 mg(-1) kg(-1) day(-1)) given group, VPA (0.5 g(-1) kg(-1) day(-1)) given group, VPA + edaravone (in same dose) given group. Edaravone and VPA were given intraperitoneally for 7 days. Biochemical parameters such as malondialdehyde, as an index of lipid peroxidation(LPO), sialic acid (SA), glutathione levels and glutathione peroxidase, glutathione-S-transferase, superoxide dismutase, catalase, myeloperoxidase, alkaline phosphatase (ALP), and tissue factor (TF) activities were determined in small intestine samples by colorimetric methods. Decreased small intestine antioxidant enzyme activities, increased LPO and SA levels, and increased activities of ALP and TF were detected in the VPA group. Based on our results edaravone may be suggested to reverse the oxidative stress and inflammation due to VPA-induced small intestine toxicity.
dc.identifier.doi10.1177/0960327114554047
dc.identifier.eissn1477-0903
dc.identifier.issn0960-3271
dc.identifier.pubmed25304967
dc.identifier.urihttps://hdl.handle.net/11424/238335
dc.identifier.wosWOS:000355334400009
dc.language.isoeng
dc.publisherSAGE PUBLICATIONS LTD
dc.relation.ispartofHUMAN & EXPERIMENTAL TOXICOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectValproic acid
dc.subjectedaravone
dc.subjectintestine
dc.subjectantioxidant and oxidant parameters
dc.subjecttissue factor activity
dc.subjectsialic acid
dc.subjectTISSUE FACTOR ACTIVITIES
dc.subjectFREE-RADICAL SCAVENGER
dc.subjectERYTHROCYTE GLUTATHIONE
dc.subjectSUPEROXIDE-DISMUTASE
dc.subjectANTIEPILEPTIC DRUGS
dc.subjectLIPID-PEROXIDATION
dc.subjectCEREBRAL-ISCHEMIA
dc.subjectSIALIC-ACID
dc.subjectCHILDREN
dc.subjectPLASMA
dc.titleEdaravone ameliorates the adverse effects of valproic acid toxicity in small intestine
dc.typearticle
dspace.entity.typePublication
local.avesis.id06113e6d-bf75-46f4-9877-803ae43f2acd
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages8
oaire.citation.endPage661
oaire.citation.issue6
oaire.citation.startPage654
oaire.citation.titleHUMAN & EXPERIMENTAL TOXICOLOGY
oaire.citation.volume34
relation.isAuthorOfPublication46115086-6b46-4ef8-aaf1-ab8eda3e917e
relation.isAuthorOfPublication.latestForDiscovery46115086-6b46-4ef8-aaf1-ab8eda3e917e

Files

Collections

Research Outputs